Viral infections and immune modulation in bladder cancer: implications for immunotherapy

Lívia Bitencourt Pascoal , Mehrsa Jalalizadeh , Gabriela Barbosa , Andrea Nazare Monteiro Rangel da Silva , Maria Alice Freitas Queiroz , Ekaterina Laukhtina , Shahrokh F. Shariat , Alessandra Gambero , Leonardo O. Reis

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002311

PDF (1457KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002311 DOI: 10.37349/etat.2025.1002311
Review
research-article
Viral infections and immune modulation in bladder cancer: implications for immunotherapy
Author information +
History +
PDF (1457KB)

Abstract

This review explores the intricate relationship between viral infections and Bacillus Calmette-Guerin (BCG) efficacy, emphasizing immune modulation mechanisms that may influence treatment outcomes. Since its introduction in 1976, intravesical BCG has been a cornerstone in managing non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumors (TURBT). Despite its success, variability in response rates suggests that host immune status, influenced by persistent infections, immunosenescence, and antigenic overload, may play a crucial role in therapeutic effectiveness. Chronic viral infections can modulate T cell responses, leading to immune exhaustion and impaired antitumor immunity. This review discusses the interplay between viral antigenic load, immune dysfunction, and tumor microenvironment remodeling, highlighting their potential impact on immunotherapies. By integrating insights from virome analysis, immune profiling, and tumor characterization, this review proposes personalized strategies to enhance immunotherapy efficacy. A deeper understanding of viral-induced immune dysregulation may improve prognostic assessment, optimize treatment protocols, and reduce healthcare costs associated with bladder cancer. Future research should focus on targeted interventions to mitigate the immunosuppressive effects of chronic infections, ultimately improving patient outcomes in NMIBC management.

Keywords

Virome / senescence / exhaustion / urothelial carcinoma / immune response

Cite this article

Download citation ▾
Lívia Bitencourt Pascoal, Mehrsa Jalalizadeh, Gabriela Barbosa, Andrea Nazare Monteiro Rangel da Silva, Maria Alice Freitas Queiroz, Ekaterina Laukhtina, Shahrokh F. Shariat, Alessandra Gambero, Leonardo O. Reis. Viral infections and immune modulation in bladder cancer: implications for immunotherapy. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002311 DOI:10.37349/etat.2025.1002311

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009; 458: 719-24.

[2]

Dyrskjøt L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, et al. Bladder cancer. Nat Rev Dis Primers. 2023; 9: 58.

[3]

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71: 209-49.

[4]

Bladder Cancer Stages [Internet]. National Cancer Institute; [cited 2025 Mar 15]. Available from: https://www.cancer.gov/types/bladder/stages#_26

[5]

Han J, Gu X, Li Y, Wu Q. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed Pharmacother. 2020; 129: 110393.

[6]

Ibrahim OM, Kalinski P. Breaking Barriers: Modulation of Tumor Microenvironment to Enhance Bacillus Calmette-Guérin Immunotherapy of Bladder Cancer. Cells. 2024; 13: 699.

[7]

Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009; 56: 247- 56.

[8]

Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and Anticancer Immunosurveillance. Cell. 2016; 165: 276-87.

[9]

Broecker F, Moelling K. The Roles of the Virome in Cancer. Microorganisms. 2021; 9: 2538.

[10]

Libbey JE, Fujinami RS. Virus-induced Immunosuppression. In: Brogden KA, Guthmiller JM, editors. Polymicrobial Diseases. Washington (DC): ASM Press; 2002.

[11]

Jalalizadeh M, Dal Col LSB, Yadollahvandmiandoab R, Reis LO. BCG Immunotherapy: Old Tool and New Concepts. In: Rezaei N, editor. Handbook of Cancer and Immunology. Cham: Springer International Publishing; 2022. pp. 1-23.

[12]

Kipps A, Stern L, Vaughan G. The duration and the possible significance of the depression of tuberculin sensitivity following measles. S Afr Med Assoc NPC. 1966; 40: 104-8.

[13]

Sinclair J. Manipulation of dendritic cell functions by human cytomegalovirus. Expert Rev Mol Med. 2008; 10: e35.

[14]

Horowitz A, Guethlein LA, Nemat-Gorgani N, Norman PJ, Cooley S, Miller JS, et al. Regulation of Adaptive NK Cells and CD8 T Cells by HLA-C Correlates with Allogeneic Hematopoietic Cell Transplantation and with Cytomegalovirus Reactivation. J Immunol. 2015; 195: 4524-36.

[15]

Zangger N, Oxenius A. T cell immunity to cytomegalovirus infection. Curr Opin Immunol. 2022; 77: 102185.

[16]

Rouse BT, Horohov DW. Immunosuppression in viral infections. Rev Infect Dis. 1986; 8: 850-73.

[17]

McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu Rev Immunol. 2019; 37: 457-95.

[18]

Reyes A, Ortiz G, Duarte LF, Fernández C, Hernández-Armengol R, Palacios PA, et al. Contribution of viral and bacterial infections to senescence and immunosenescence. Front Cell Infect Microbiol. 2023; 13: 1229098.

[19]

Müller L, Di Benedetto S. Immunosenescence and Cytomegalovirus: Exploring Their Connection in the Context of Aging, Health, and Disease. Int J Mol Sci. 2024; 25: 753.

[20]

Ishii T, Sasaki Y, Maeda T, Komatsu F, Suzuki T, Urita Y. Clinical differentiation of infectious mononucleosis that is caused by Epstein-Barr virus or cytomegalovirus: A single-center case-control study in Japan. J Infect Chemother. 2019; 25: 431-6.

[21]

Sharma S, Thomas PG. The two faces of heterologous immunity: protection or immunopathology. J Leukoc Biol. 2014; 95: 405-16.

[22]

Yadollahvandmiandoab R, Jalalizadeh M, Buosi K, Garcia-Perdomo HA, Reis LO. Immunogenic Cell Death Role in Urothelial Cancer Therapy. Curr Oncol. 2022; 29: 6700-13.

[23]

Jenkins E, Whitehead T, Fellermeyer M, Davis SJ, Sharma S. The current state and future of T-cell exhaustion research. Oxf Open Immunol. 2023; 4: iqad006.

[24]

Delaunay T, Achard C, Grégoire M, Tangy F, Boisgerault N, Fonteneau JF. A Functional Assay to Determine the Capacity of Oncolytic Viruses to Induce Immunogenic Tumor Cell Death. In: Engeland CE, editor. Oncolytic Viruses. New York, NY: Springer New York; 2020. pp. 127-32.

[25]

zur Hausen H. Viruses in human cancers. Science. 1991; 254: 1167-73.

[26]

Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022; 23: 487-500.

[27]

Chiaravalli M, Spring A, Agostini A, Piro G, Carbone C, Tortora G. Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers. Cells. 2022; 11: 3033.

[28]

Sprooten J, Garg AD. Chapter Three - Type I interferons and endoplasmic reticulum stress in health and disease. In: Kepp O, Galluzzi L, editors. International Review of Cell and Molecular Biology. Academic Press; 2020. pp. 63-118.

[29]

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007; 13: 1050-9.

[30]

Fucikova J, Spisek R, Kroemer G, Galluzzi L. Calreticulin and cancer. Cell Res. 2021; 31: 5-16.

[31]

Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019; 16: 356-71.

[32]

Hennessy ML, Bommareddy PK, Boland G, Kaufman HL. Oncolytic Immunotherapy. Surg Oncol Clin N Am. 2019; 28: 419-30.

[33]

de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020; 8: e180-90.

[34]

zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2: 342-50.

[35]

Zhang J, Shi Z, Xu X, Yu Z, Mi J. The influence of microenvironment on tumor immunotherapy. FEBS J. 2019; 286: 4160-75.

[36]

Liang G, Bushman FD. The human virome: assembly, composition and host interactions. Nat Rev Microbiol. 2021; 19: 514-27.

[37]

Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature. 1993; 362: 758-61.

[38]

Wherry EJ. T cell exhaustion. Nat Immunol. 2011; 12: 492-9.

[39]

Strandgaard T, Lindskrog SV, Nordentoft I, Christensen E, Birkenkamp-Demtröder K, Andreasen TG, et al. Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with Bacillus Calmette-Guérin Failure in Patients with Non-muscle-invasive Bladder Cancer. Eur Urol. 2022; 82: 646-56.

[40]

Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol. 2003; 77: 4911-27.

[41]

Liu Z, Liang Q, Ren Y, Guo C, Ge X, Wang L, et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct Target Ther. 2023; 8: 200.

[42]

Chou JP, Effros RB. T cell replicative senescence in human aging. Curr Pharm Des. 2013; 19: 1680-98.

[43]

Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021; 19: 759-73.

[44]

Yu C, He S, Zhu W, Ru P, Ge X, Govindasamy K. Human cytomegalovirus in cancer: the mechanism of HCMV-induced carcinogenesis and its therapeutic potential. Front Cell Infect Microbiol. 2023; 13: 1202138.

[45]

Horowitz A. Abstract IA007: Tumor HLA-E expression and cytomegalovirus infection modulate NK cell activity in human bladder cancer. Clin Cancer Res. 2024; 30: IA007.

[46]

Llewellyn MA, Gordon NS, Abbotts B, James ND, Zeegers MP, Cheng KK, et al. Defining the frequency of human papillomavirus and polyomavirus infection in urothelial bladder tumours. Sci Rep. 2018; 8: 11290.

[47]

Kao HL, Lai CR, Ho HL, Pan CC. Molecular typing for detection of high-risk human papillomavirus is a useful tool for distinguishing primary bladder carcinoma from secondary involvement of uterine cervical carcinoma in the urinary bladder. Histopathology. 2016; 68: 513-9.

[48]

Schmid SC, Thümer L, Schuster T, Horn T, Kurtz F, Slotta-Huspenina J, et al. Human papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational study. Infect Agent Cancer. 2015; 10: 31.

[49]

Li N, Yang L, Zhang Y, Zhao P, Zheng T, Dai M. Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis. 2011; 204: 217-23.

[50]

Patel PD, Alghareeb R, Hussain A, Maheshwari MV, Khalid N. The Association of Epstein-Barr Virus With Cancer. Cureus. 2022; 14: e26314.

[51]

Zhang Q, Xu M. EBV-induced T-cell responses in EBV-specific and nonspecific cancers. Front Immunol. 2023; 14: 1250946.

[52]

Chuang KL, Pang ST, Liao SK, Wu CT, Chang YH, Chuang HC, et al. Epstein-Barr virus DNA load in tumour tissues correlates with poor differentiation status in non-muscle invasive urothelial carcinomas. BJU Int. 2011; 107: 150-4.

[53]

Chen Y, Trofe J, Gordon J, Du Pasquier RA, Roy-Chaudhury P, Kuroda MJ, et al. Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol. 2006; 80: 3495-505.

[54]

Sharma R, Zachariah M. BK Virus Nephropathy: Prevalence, Impact and Management Strategies. Int J Nephrol Renovasc Dis. 2020; 13: 187-92.

[55]

Cayres-Vallinoto IM, Vallinoto AC, Pena GP, Azevedo VN, Machado LF, Ishak Mde O, et al. JC virus/human immunodeficiency virus 1 co-infection in the Brazilian Amazonian region. Braz J Infect Dis. 2016; 20: 360-4.

[56]

Taherkhani R, Farshadpour F. BK and JC polyomaviruses and risk of urothelial bladder carcinoma: a preliminary study in the northern shores of Persian Gulf, Iran. Infect Agent Cancer. 2022; 17: 50.

[57]

Querido S, Fernandes I, Weigert A, Casimiro S, Albuquerque C, Ramos S, et al. High-grade urothelial carcinoma in a kidney transplant recipient after JC virus nephropathy: The first evidence of JC virus as a potential oncovirus in bladder cancer. Am J Transplant. 2020; 20: 1188-91.

[58]

Hrbáček J, Hanáček V, Kadlečková D, Cirbusová A, Čermák P, Tachezy R, et al. Urinary shedding of common DNA viruses and their possible association with bladder cancer: a qPCR-based study. Neoplasma. 2023; 70: 311-8.

[59]

Starrett GJ, Yu K, Golubeva Y, Lenz P, Piaskowski ML, Petersen D, et al. Evidence for virus-mediated oncogenesis in bladder cancers arising in solid organ transplant recipients. Elife. 2023; 12: e82690.

[60]

Wang Y, Yan S, Liu Y, Yan Z, Deng W, Geng J, et al. Dynamic viral integration patterns actively participate in the progression of BK polyomavirus-associated diseases after renal transplantation. Am J Transplant. 2023; 23: 1694-708.

PDF (1457KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉